Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


10th Euro-Global Conference on Infectious Diseases

Rome, Italy

Taruna Arora

Taruna Arora

National Institute of Malaria Research, India

Title: Assessing the quality of antimalarial drugs from India using minilab: A field study


Biography: Taruna Arora


Substandard and counterfeit antimalarial medicines poses a serious threat to public health. These medicines  increases  the mortality by decreasing efficacy; it also increases the threat of emergence of drug resistance, adverse effect from incorrect excipients/ active ingredients  which may be potentially dangerous to the patients. Owing to this, a pilot study was conducted to survey quality of drugs collected from different malaria endemic areas of India.  The survey was conducted in different geographical regions on the basis of malaria endemicity i.e. Uttar Pradesh (U.P.), Mizoram, Meghalaya, Gujarat, Madhya Pradesh. A mystery shopper approach was used for collection of samples.  The quality of antimalarial drugs from these areas were assessed by using Global Pharma Health Fund Minilab test kit. This includes physical/visual inspection and disintegration test, thin-layer chromatography.  High performance liquid chromatography was carried out for quantitative assessment of active pharmaceutical ingredient.  A total of 150 antimalarial samples were collected. These samples includes 55 (Chloroqunie), 50 (Artemether Lumefantrine), 14 (Artesunate Sulphadoxine-Pyrimethamine), 31 (Primaquine). These samples were assessed by quality using GPHF minilab lab kit. In this study 98% of the tablets passed minilab disintegration, 2% consisting did not passed disintegration test.  99% of samples passed preliminary Qualitative TLC test when compared with 100% and 80% of the standards. 96% of samples passed quantitative HPLC test, 4% of samples (contained low active pharmaceutical ingredient) did not passed this test. The substandard drugs circulating in the market causes drug resistance, treatment failure and finally leads to death. Additional analysis such as post-marketing surveillance should be done so that good quality antimalarials reached to the population.